<DOC>
	<DOCNO>NCT01620359</DOCNO>
	<brief_summary>The goal prospective , non-randomized , single-arm , multi site , international study develop data evaluate safety effectiveness ExAblate MRgFUS system ablation breast cancer MRI . The goal MRgFUS ablation breast cancer plan ablate entire tumor volume treatable device accessible location .</brief_summary>
	<brief_title>Study ExAblate Focused Ultrasound Ablation Breast Cancer</brief_title>
	<detailed_description>In international , non-randomized , single-arm study , total 200 patient positive diagnosis invasive breast cancer schedule surgical resection enrol trial . Eligible participant evaluate treated ExAblate breast ablation prior plan definitive surgical treatment . After 10 21 day post ExAblate therapy , study participant another contrast-enhanced MR imaging examination . Their planned tumor excision complete later 14 day contrast-enhanced , post ExAblate procedure MR image examination . Additionally , end point study compare CORE Pathology Lab result .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Women age 18 year invasive breast cancer 2 . Patient contrastenhanced MR image confirm single focal breast lesion le 2 cm diameter 3 . Lesion clearly see contrastenhanced MR treatable location 4 . Patient willing undergo schedule sentinel lymph node biopsy 5 . Patient schedule consented surgical ( lumpectomy mastectomy ) resection breast cancer 6 . Patient clinical Stage I disease : T1 M0 N0 7 . Patient sign inform consent form screening , SLNB , ablation , followup visit . 1 . Invasive lobular carcinoma ; 2 . DCIS without invasive component core biopsy ; 3 . Tamoxifen , Aromatase Inhibitors , Neoadjuvant chemotherapy within 30 day prior ExAblate . 4 . Prior XRT ablative therapy target breast ; 5 . Patients currently receive anticoagulation therapy within previous 14 day ; 6 . Lesions difficult target ( &lt; 1 cm skin , nipple rib cage ) , visualized pretherapy MRI ; 7 . Microcalcifications sign breast cancer image study ; 8 . Extensive intraductal component ( EIC ) core biopsy . 9 . Patients breast implant ; 10 . Patients prior surgical clip marker site breast tumor ; 11 . Patients severe cerebrovascular disease ( multiple CVA CVA within 6 month ) ; 12. hemolytic anemia ( hematocrit &lt; 30 ) ; 13 . Pregnant lactating , postpartum woman ; 14 . Patient overall health status ASA &gt; 2 15 . Patient active ongoing infection body site ; 16 . Poor blood glucose control . 17 . Severe hypertension 18 . Patients unstable cardiac status 19 . Contraindication MR ExAblate ablation therapy 20 . Patient history deep vein thrombosis 21 . With history pulmonary embolism ; 22 . Patient sleep apnea ; 23 . Patient airway problem ; 24 . Patient severe claustrophobia ; 25 . Patient nonMRI compatible implant metal device ; 26 . Patient difficulty lie prone still 3 hour ( 180 minute ) MR unit ; 27 . Patient fit comfortably magnet patient &gt; 250 lb ; 28 . Patient prior reaction contrast agent ; 29 . Patient history grand mal seizure ; 30 . Patient severely impair renal function estimate glomerular filtration rate &lt; 30 mL/min/1.73m2 and/or dialysis ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Breast tumor</keyword>
	<keyword>stage 1 disease</keyword>
	<keyword>T1 M0 N0</keyword>
</DOC>